Recent measures aimed at curbing opioid overprescribing make it hard for those with chronic pain to get treatment.
Opioid medicines – such as oxycodone, morphine, fentanyl and codeine – are essential medicines and provide relief to many people with this type of pain.
Over the past decade, measures have been introduced in Australia to curb growing rates of opioid use and harms. But this has come at the expense of access for some people who genuinely need them.
In our new study, one-third of participants prescribed opioids long-term for chronic, non-cancer pain had difficulties getting ongoing prescriptions.
In 2018, codeine was made a “prescription-only” medicine. In the same year, Australia’s Chief Medical Officer wrote to doctors prescribing a lot of opioids to encourage them to consider reducing their prescribing.
We’re underaking a long-term study of just over 1,500 Australians prescribed opioids for chronic non-cancer pain. We started asking questions about accessing opioid prescriptions in our 2018 interviews with participants.
These weren’t prescriptions for new pain conditions, but ongoing prescriptions for people who had been using these medicines for four years, on average, and living with pain for ten years, before the study.
Opioids can cause significant harm
Over the past 30 years, the amount of opioids (doses per Australian per day) dispensed on the Pharmaceutical Benefits Scheme (PBS) has increased four-fold.
Pharmaceutical opioids are now involved in more deaths than heroin. Pharmaceutical opioids also contribute more to poisoning-related hospital visits than heroin, with hospitalisations doubling since 1999.
So what did our research find?
In our study, one in five people reported problems relating to accessing doctors.
As opioids become more restricted, people may need to visit their doctor more frequently because they’re given smaller pack sizes and fewer repeats. They may be put in a position where they’re unable to get prescriptions if doctors aren’t available.
Opioids can cause dependence and tolerance with continuous and long-term use. However, sudden interruptions to opioid medicine supply may place people at risk of experiencing unpleasant withdrawal symptoms such as nausea and vomiting, flu symptoms, and muscle cramping.
One in ten people in our study reported their doctor wanted to reduce or stop opioid medicines against their wishes.
Patients and doctors need to work together
More doctors are practising “opioid tapering” (reducing opioid doses over time), especially in the United States, following the release in 2016 of Centers for Disease Control and Prevention (CDC) guidelines for chronic pain.
However, there were soon reports of opioids being ceased without reducing the dose first, which risks withdrawal. This prompted the CDC to warn that applying guidelines without adequate care could harm patients.
Some studies suggest pain may even improve when opioids are stopped. However, participants in these studies are usually enrolled in special pain programs. These programs are notoriously difficult to access in Australia and it is common to wait months to years for services. Increased investment in pain services and programs is needed.
Balancing benefits and harms
Since we conducted our study, new restrictions introduced in 2020 reduced the quantities of opioids that can be prescribed on the PBS. For most opioids, doctors can only supply quantities and repeats for up to three months at a time.
So it’s likely to have become harder for people with pain to access pain medicines. In a survey released last month by Painaustralia, half of the respondents said their pain management was worse, and their pain was more severe, because of the changes.
When it comes to using opioids for chronic non-cancer pain, it’s important to balance both benefits and harms. Potential opioid-related harms need to be recognised and addressed. At the same time, adequate treatment of pain is essential, and we need to make sure people don’t suffer harms due to changes to opioid access.
The needs of people who live with pain and the impact of restrictions on them need to remain at the centre of all decisions and discussions about opioids.
Ria Hopkins, PhD Candidate, National Drug and Alcohol Research Centre, UNSW Sydney and Natasa Gisev, Clinical pharmacist and Scientia Senior Lecturer at the National Drug and Alcohol Research Centre, UNSW Sydney